首页> 外文OA文献 >New Research Trends in Gastroenterology: pancreatitis is in Danger
【2h】

New Research Trends in Gastroenterology: pancreatitis is in Danger

机译:胃肠病学的新研究趋势:胰腺炎正处于危险之中

摘要

Introduction: By definition research and development (R&D) is a process of creating new products, processes and technologies that can be used and marketed for mankind’s benefit in the future. The largest investor into and key player in health related R&D is the USA. The second largest investor into R&D is China and there is a strong will there to become a key leader in health related R&D and innovation in the future. In Europe, Germany, France, UK, Switzerland and Spain are the largest health related R&D spenders. Northern European countries are emerging from smaller countries thanks to their more intense investments in research and education. Remarkably, Central and Eastern European countries have little sources for health-related R&D. udIn the last decade there was a serious global decrease in the business investment due to several reasons including the global financial crisis from 2008 through 2010 affecting seriously both central and industrial funding of research.udObjectives: 1) to understand the research trends in the field of gastroenterology and highlight the most endangered areas based on the gastrointestinal research publications in the last 50 years and 2) to identify possibilities of developing a better environment for pancreatic research and improvement of patient care within the framework of the Hungarian Pancreatic Study Group.udMethods: We searched for PubMed hits for gastrointestinal (GI) diseases for the 1965–2015 period. Overall, 1,554,325 articles were analyzed. Since pancreatology was identified as the most endangered field of research within gastroenterology, we carried out a detailed evaluation of research activity in pancreatology.udResults: In 1965, among the major benign GI disorders, 51.9% of the research was performed on hepatitis, 25.7% on pancreatitis, 21.7% on upper GI diseases and only 0.7% on the lower GI disorders. Half a century later, in 2015, research on hepatitis and upper GI diseases had not changed significantly; however, studies on pancreatitis had dropped to 10.7%, while work on the lower GI disorders had risen to 23.4%. With regard to the malignant disorders (including liver, gastric, colon, pancreatic and oesophageal cancer), no such large-scale changes were observed in the last 50 years. Detailed analyses revealed that besides the drop in research activity in pancreatitis, there are serious problems with the quality of the studies as well. Only 6.8% of clinical trials on pancreatitis were registered and only 5.5% of these registered trials were multicentre and multinational (more than five centres and nations), i.e., the kind that provides the highest level of impact and evidence level.udIn the second part of the thesis I describe the steps the Hungarian Pancreatic Study Group has made as a start for improvement. The activity of the study group includes the development of the Pancreatic Registry and Biobank, initiation of observational clinical trials, also the adaptation of the international evidence based guidelines and disseminating them through publication, trainings and courses.udConclusions: There has been a clear drop in research activity in pancreatitis. New international networks and far more academic R&D activities should be established in order to find the first therapy specifically for acute pancreatitis. The analysis has also confirmed that multinational-multicentre trials are of higher quality, providing higher evidence and impact, but the share of the multinational-multicentre studies are very low. Consequently, there is still much space for improving both the quantity and quality of research activity in the field of pancreatology.udCurrent barriers in pancreatology should be eliminated by an international research network, cooperation between pancreatic communities in different countries that will result in more and higher quality prospective multicenter observational clinical trials and randomized controlled trials, evidence based guidelines available in more countries, improvement of compliance through education, influence on national financing of pancreatology, ultimately in quality research. ud
机译:简介:从定义上讲,研发(R&D)是创建新产品,过程和技术的过程,这些新产品,过程和技术可用于未来人类的利益和销售。美国是卫生相关研发的最大投资方和主要参与者。研发的第二大投资者是中国,并且将来有很大的希望成为健康相关研发和创新的主要领导者。在欧洲,德国,法国,英国,瑞士和西班牙是与健康相关的研发支出最大的国家。北欧国家从较小的国家中崛起,这要归功于它们在研究和教育方面的加大投入。值得注意的是,中欧和东欧国家很少有与卫生相关的研发资源。 ud在过去十年中,由于多种原因,全球商业投资出现了严重减少,其中包括2008年至2010年的全球金融危机严重影响了中央和工业研究资金。 ud目标:1)了解企业的​​研究趋势在胃肠病学领域,并根据最近50年的胃肠研究出版物,重点介绍最危险的地区; 2)在匈牙利胰腺研究小组的框架内,确定为胰腺研究创造更好的环境并改善患者护理的可能性。 udMethods:我们搜索了1965-2015年期间胃肠道(GI)疾病的PubMed命中数据。总共分析了1,554,325条文章。由于胰腺病被认为是胃肠病学中最危险的研究领域,因此我们对胰腺病研究活动进行了详细评估。 ud结果:1965年,在主要的良性胃肠道疾病中,有51.9%的研究是针对肝炎的,占25.7%。胰腺炎的百分比为7%,上消化道疾病的百分比为21.7%,下消化道疾病的比例仅为0.7%。半个世纪后的2015年,关于肝炎和上消化道疾病的研究没有显着变化;然而,有关胰腺炎的研究已降至10.7%,而针对较低胃肠道疾病的研究已上升至23.4%。关于恶性疾病(包括肝癌,胃癌,结肠癌,胰腺癌和食道癌),在过去的50年中没有观察到如此大规模的变化。详细的分析显示,除了胰腺炎的研究活动下降之外,研究质量也存在严重问题。仅注册了6.8%的胰腺炎临床试验,而这些注册试验中只有5.5%是多中心和跨国的(超过五个中心和国家),即提供最高水平的影响和证据的那种。在论文的一部分中,我描述了匈牙利胰腺研究小组作为改进起点而采取的步骤。该研究小组的活动包括胰腺登记处和生物库的开发,观察性临床试验的启动,国际循证指南的改编以及通过出版,培训和课程进行传播。 ud结论:明显下降在胰腺炎的研究活动中。应该建立新的国际网络和更多的学术研发活动,以便找到专门针对急性胰腺炎的第一种疗法。分析还证实,多国-多中心试验的质量较高,提供了更高的证据和影响力,但多国-多中心试验的份额非常低。因此,在胰腺病学领域仍有大量空间可以提高研究活动的数量和质量。 ud应通过国际研究网络消除当前的胰腺病学障碍,不同国家的胰腺病社区之间的合作将带来更多和更多的成果。更高质量的前瞻性多中心观察性临床试验和随机对照试验,更多国家/地区提供的循证指南,通过教育提高依从性,对国家胰腺癌筹资的影响,最终在质量研究中。 ud

著录项

  • 作者

    Szentesi Andrea;

  • 作者单位
  • 年度 2017
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号